Table 1 Association results of eight independent variants of NPC genetic susceptibility in discovery, validation, and combined phases.
Variants | Locus | Markers in LD | EA/OA | MAF | Discovery (n = 3047) | Validation (n = 2642) | Combined (n = 5689) | Conditional analysis | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | P | |||||
rs9391681 | intergenic RPP21* HLA-E | HLA-Aaa-C9911 | C/T | 0.17/0.23/0.12 | 2.30 (2.00–2.64) | 1.73E−31 | 1.90 (1.64–2.21) | 3.68e−17 | 2.11 (1.90–2.33) | 1.50e−46 | – |
HLA-A amino acid Q62 | HLA-A | rs28605807 | P/Ab | 0.33/0.26/0.39 | 0.54 (0.48–0.61) | 1.35E−26 | 0.58 (0.51–0.65) | 7.11e−19 | 0.56 (0.51–0.61) | 6.27e−44 | 1.68e−24 |
rs2523589 | HLA-B | rs9405084a | G/T | 0.30/0.24/0.35 | 0.56 (0.50–0.63) | 1.05E−23 | 0.62 (0.55–0.70) | 4.15e−14 | 0.59 (0.54–0.64) | 1.77e−36 | 3.26e−19 |
HLA-B*55:02 | HLA-B | – | P/Ab | 0.018/0.0047/0.031 | 0.13 (0.070–0.23) | 1.99E−11 | 0.18 (0.10–0.32) | 4.81e−09 | 0.15 (0.10–0.23) | 3.59e−19 | 8.79e−14 |
rs2517664 | TRIM31 | rs1116222, rs2844796a | T/C | 0.030/0.014/0.046 | 0.27 (0.19–0.39) | 7.77E−13 | 0.31 (0.21–0.45) | 1.66e−09 | 0.29 (0.22–0.37) | 6.38e−21 | 2.55e−12 |
rs9265975 | HLA-B | rs24982077 | A/G | 0.10/0.072/0.13 | 0.46 (0.39–0.55) | 4.41E−17 | 0.56 (0.47–0.68) | 1.15e−09 | 0.51 (0.45–0.58) | 6.77e−25 | 1.61e−09 |
rs9461780 | HLA-DQA1 | – | T/C | 0.071/0.049/0.091 | 0.51 (0.42–0.62) | 2.81E−11 | 0.55 (0.44–0.70) | 6.85e−07 | 0.52 (0.45–0.61) | 4.38e−17 | 2.60e−14 |
rs117495548 | TRIM39/ TRIM39-RPP21 | rs148603250a | G/A | 0.020/0.0094/0.030 | 0.36 (0.24–0.54) | 8.56E−07 | 0.27 (0.16–0.43) | 1.19e−07 | 0.31 (0.23–0.43) | 4.53e−13 | 2.24e−06 |